These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21797749)

  • 1. A role for GRK2 in myocardial ischemic injury: indicators of a potential future therapy and diagnostic.
    Brinks H; Das A; Koch WJ
    Future Cardiol; 2011 Jul; 7(4):547-56. PubMed ID: 21797749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Level of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms.
    Brinks H; Boucher M; Gao E; Chuprun JK; Pesant S; Raake PW; Huang ZM; Wang X; Qiu G; Gumpert A; Harris DM; Eckhart AD; Most P; Koch WJ
    Circ Res; 2010 Oct; 107(9):1140-9. PubMed ID: 20814022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression.
    Travers JG; Kamal FA; Valiente-Alandi I; Nieman ML; Sargent MA; Lorenz JN; Molkentin JD; Blaxall BC
    J Am Coll Cardiol; 2017 Aug; 70(8):958-971. PubMed ID: 28818206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiofrequency Renal Denervation Protects the Ischemic Heart via Inhibition of GRK2 and Increased Nitric Oxide Signaling.
    Polhemus DJ; Gao J; Scarborough AL; Trivedi R; McDonough KH; Goodchild TT; Smart F; Kapusta DR; Lefer DJ
    Circ Res; 2016 Jul; 119(3):470-80. PubMed ID: 27296507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G protein-coupled receptor kinase 2 in patients with acute myocardial infarction.
    Santulli G; Campanile A; Spinelli L; Assante di Panzillo E; Ciccarelli M; Trimarco B; Iaccarino G
    Am J Cardiol; 2011 Apr; 107(8):1125-30. PubMed ID: 21296320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo.
    Inagaki K; Chen L; Ikeno F; Lee FH; Imahashi K; Bouley DM; Rezaee M; Yock PG; Murphy E; Mochly-Rosen D
    Circulation; 2003 Nov; 108(19):2304-7. PubMed ID: 14597593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G protein coupled receptor kinase-2 upregulation causes κ-opioid receptor desensitization in diabetic heart.
    Chen X; Zhao S; Xia Y; Xiong Z; Li Y; Tao L; Zhang F; Wang X
    Biochem Biophys Res Commun; 2017 Jan; 482(4):658-664. PubMed ID: 27865836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GRK2 inhibition in heart failure: something old, something new.
    Lymperopoulos A; Rengo G; Koch WJ
    Curr Pharm Des; 2012; 18(2):186-91. PubMed ID: 22229578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulator of G Protein Signaling 6 Protects the Heart from Ischemic Injury.
    Rorabaugh BR; Chakravarti B; Mabe NW; Seeley SL; Bui AD; Yang J; Watts SW; Neubig RR; Fisher RA
    J Pharmacol Exp Ther; 2017 Mar; 360(3):409-416. PubMed ID: 28035008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives.
    Guccione M; Ettari R; Taliani S; Da Settimo F; Zappalà M; Grasso S
    J Med Chem; 2016 Oct; 59(20):9277-9294. PubMed ID: 27362616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation.
    Sack MN; Yellon DM
    J Am Coll Cardiol; 2003 Apr; 41(8):1404-7. PubMed ID: 12706939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. betaARKct: a therapeutic approach for improved adrenergic signaling and function in heart disease.
    Brinks H; Koch WJ
    J Cardiovasc Transl Res; 2010 Oct; 3(5):499-506. PubMed ID: 20623214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury.
    Bao W; Hu E; Tao L; Boyce R; Mirabile R; Thudium DT; Ma XL; Willette RN; Yue TL
    Cardiovasc Res; 2004 Feb; 61(3):548-58. PubMed ID: 14962485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Nicotinamidoethyl nitrale (2-NN) protects myocardium in ischemia and reperfusion via the protein kinase C pathway.
    Watanabe M; Mizuno T; Tanaka H; Sakamoto T; Sunamori M
    J Cardiovasc Surg (Torino); 2002 Dec; 43(6):817-25. PubMed ID: 12483172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GRK2 and GRK5 as therapeutic targets and their role in maladaptive and pathological cardiac hypertrophy.
    Lieu M; Koch WJ
    Expert Opin Ther Targets; 2019 Mar; 23(3):201-214. PubMed ID: 30701991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypothesis: Paroxetine, a G Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor Reduces Morbidity and Mortality in Patients With Heart Failure.
    Powell JM; Ebin E; Borzak S; Lymperopoulos A; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2017 Jan; 22(1):51-53. PubMed ID: 27222484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure.
    Rengo G; Galasso G; Femminella GD; Parisi V; Zincarelli C; Pagano G; De Lucia C; Cannavo A; Liccardo D; Marciano C; Vigorito C; Giallauria F; Ferrara N; Furgi G; Filardi PP; Koch WJ; Leosco D
    Eur J Prev Cardiol; 2014 Jan; 21(1):4-11. PubMed ID: 23689525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preconditioning and postconditioning: underlying mechanisms and clinical application.
    Hausenloy DJ; Yellon DM
    Atherosclerosis; 2009 Jun; 204(2):334-41. PubMed ID: 19081095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes.
    Potier L; Waeckel L; Vincent MP; Chollet C; Gobeil F; Marre M; Bruneval P; Richer C; Roussel R; Alhenc-Gelas F; Bouby N
    J Pharmacol Exp Ther; 2013 Jul; 346(1):23-30. PubMed ID: 23591995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.